SOURCE: Endonovo Therapeutics, Inc.

Endonovo Therapeutics, Inc.

June 29, 2016 09:32 ET

Endonovo Therapeutics Files Continuation Patent for Producing Adult Stem Cell Secretome

LOS ANGELES, CA--(Marketwired - Jun 29, 2016) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a developer of bioelectronic devices and medicines, announced today that it has filed a continuation patent, titled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells." Endonovo's patent filing covers a process for the production of the adult stem cell secretome and its corresponding administration as a next generation fully human biologic.

This patent filing is a continuation of the prior announcement on March 30, 2016.

Adult stem cells, such as Mesenchymal Stem Cells ("MSCs") isolated from tissues, including bone marrow and the human umbilical cord release a plethora of cytokines, interleukins, prostaglandins, and growth factors, referred to collectively as the secretome.

Many studies have ascertained and continue to clarify that the therapeutic potential of adult stem cells is linked to their ability to secrete therapeutic proteins and other molecules. However, human cells typically secrete very low concentrations of these therapeutic cytokines and growth factors and have required the use of recombinant DNA technology to develop them as biologics.

According to Thomson Reuters, the biologics sector is set for an unprecedented level of activity as U.S. companies have rapidly increased their development of biologics during the past five years. The market for next-generation biologics is estimated to reach a value of $30 billion by 2024, according to Visiongain. These next-generation biologics will seek to address shortcomings in current therapies, including inconvenient dosing and potential side-effects.

Endonovo CEO, Alan Collier commented, "We are largely looking at adult stem cells as tiny drug factories capable of producing the most complex and hard to produce drugs known as biologics."

Mr. Collier went on to say, "One of the benefits of our approach in using the secretome as a next generation fully human biologic is that it is much easier to manufacture than conventional biologics manufactured by synthetic or recombinant DNA technology, which could result in better outcomes for patients and lower costs."

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo's Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo's Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company's initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Contact Information